2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1607

B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Abstract Number: 1718

B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Abstract Number: 2870

B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Abstract Number: 2694

B Lymphocyte Stimulator (BLyS) Promotes Dysregulated Monocyte Function in Systemic Lupus Erythematosus(SLE)
Abstract Number: 2872

B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snRNP Reactive B Cells in BXD2 Mice
Abstract Number: 2734

B55β Regulates T Cell Survival through the Modulation of AKT during Cytokine Deprivation
Abstract Number: 2247

Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss
Abstract Number: L17

Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage
Abstract Number: 1151

Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States
Abstract Number: 1641

Baseline Factors That Predict High BLyS Levels in Patients with Systemic Lupus Erythematosus (SLE) and High Disease Activity
Abstract Number: 2134

Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients
Abstract Number: 2927

Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Abstract Number: 2839

BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation
Abstract Number: 1212

Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Abstract Number: 671

Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Abstract Number: 7

Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Abstract Number: 2103

Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting
Abstract Number: 2313

Best Practices for Best Practice Alerts: Evaluation of a Best Practice Alert to Detect Chronic Glucocorticoid Use
Abstract Number: 2815

Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
Abstract Number: 569

Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors
Abstract Number: 1545

Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
Abstract Number: 425

Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis
Abstract Number: 2166

Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization
Abstract Number: 501

Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Abstract Number: 1049

Bioactive TGF-β Is Present on Bovine Milk-Derived Exosomes: Consequences for Patients?
Abstract Number: 941

Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success
Abstract Number: 499

Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic
Abstract Number: 2036

Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA
Abstract Number: 115

Biologic Dmards Modify the Association Between Patient Expectations and Outcomes of Total Knee Replacement in Rheumatoid Arthritis Patients
Abstract Number: 2300

Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience
Abstract Number: 280

Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Abstract Number: 2514

Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Abstract Number: 811

Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Abstract Number: 911

Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-Kb-Mediated Inflammation
Abstract Number: 630

Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis
Abstract Number: 373

Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis
Abstract Number: 629

Biomarkers of Chondrocyte Activity Are Increased in Psoriasis Arthritis and Spondyloarthritis
Abstract Number: 808

Biomarkers of Disease Activity in Vasculitis
Abstract Number: 1652

Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus
Abstract Number: 1866

Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Abstract Number: 831

Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)
Abstract Number: 588

Blacks with As Have Greater Disease Severity Than Whites
Abstract Number: 2795

Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Abstract Number: 1899

Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis
Abstract Number: 965

Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis
Abstract Number: 1510

Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Abstract Number: 2194

Blue Digit Syndrome: The Rheumatologist’s Perspective
Abstract Number: 2793

BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis
Abstract Number: 1017

BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1
Abstract Number: 45

Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men
Abstract Number: 338

Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Abstract Number: 1424

Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-Ray Erosion Detection
Abstract Number: 2130

Bone Microstructure in Patients with Cutaneous Psoriasis and No History of Psoriatic Arthritis Shows Bone Anabolic Changes at a Greater Extent Than in Healthy Controls
Abstract Number: 1683

Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Abstract Number: L20

BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Abstract Number: 2657

Brain Gray and White Matter Volume Losses and Their Associations with Glucocorticoid Use in Patients with Newly Diagnosed Systemic Lupus Erythematosus (SLE) – a Prospective MR Study
Abstract Number: 656

Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice
Abstract Number: 2871

Break of Anergy in Human Autoreactive B Cells By T Helper Signals Restores B Cell Receptor Signaling Capacity and Is Dependent on Upregulation of CD45 Phosphatase Activity-a Possible Novel Mechanism of Breech of B Cell Tolerance in Rheumatic Diseases
Abstract Number: 659

Breakdown of Tolerance at the Tissue Level in Systemic Autoimmunity: Role of Tissue-Resident Dendritic Cells
Abstract Number: 1333

Bridging the Social Support Needs Gap for African American Women with Systemic Lupus Erythematosus through the Chronic Disease Self-Management Program
Abstract Number: 1728

Bromodomain Inhibitor JQ1 Modulates Collagen Processing and Ameliorates Bleomycin Induced Dermal Fibrosis in Mice
Abstract Number: 433

Bronchiectasis: A Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis
Abstract Number: 2752

Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Abstract Number: 2125

Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].